Globus Medical Q2 EPS Forecast Lowered by Zacks Research

Key Points

• Zacks Research has reduced its Q2 2025 earnings per share (EPS) estimate for Globus Medical from $0.78 to $0.76, reflecting concerns about the company's financial performance.
• Globus Medical reported a Q1 earnings miss of $0.68 EPS against expectations of $0.74, alongside a revenue decline of 1.4% compared to the same quarter last year.
• The company has implemented a $500 million stock repurchase program, signaling confidence from its Board of Directors that the stock is currently undervalued.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Research analysts at Zacks Research cut their Q2 2025 earnings estimates for shares of Globus Medical in a note issued to investors on Wednesday, July 23rd. Zacks Research analyst R. Department now expects that the medical device company will post earnings per share of $0.76 for the quarter, down from their prior estimate of $0.78. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical's FY2025 earnings at $3.14 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $0.93 EPS, Q4 2026 earnings at $0.84 EPS, FY2026 earnings at $3.57 EPS, Q1 2027 earnings at $0.84 EPS and FY2027 earnings at $4.02 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical device company reported $0.68 EPS for the quarter, missing analysts' consensus estimates of $0.74 by ($0.06). The company had revenue of $598.12 million for the quarter, compared to analysts' expectations of $629.74 million. Globus Medical had a return on equity of 10.52% and a net margin of 7.39%. The business's revenue was down 1.4% compared to the same quarter last year. During the same period last year, the business posted $0.72 earnings per share.

Other research analysts have also recently issued research reports about the stock. Truist Financial cut their price objective on shares of Globus Medical from $80.00 to $68.00 and set a "hold" rating for the company in a report on Monday, May 12th. Barclays reissued an "overweight" rating on shares of Globus Medical in a research note on Tuesday, June 10th. Morgan Stanley cut their target price on shares of Globus Medical from $75.00 to $68.00 and set an "overweight" rating for the company in a research note on Tuesday, July 15th. JMP Securities reissued a "market perform" rating on shares of Globus Medical in a research note on Tuesday, May 27th. Finally, Piper Sandler cut their target price on shares of Globus Medical from $100.00 to $80.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $90.09.

Globus Medical Trading Down 0.9%

Shares of NYSE:GMED traded down $0.48 on Monday, hitting $52.98. 174,178 shares of the company were exchanged, compared to its average volume of 1,428,085. Globus Medical has a 1-year low of $51.87 and a 1-year high of $94.93. The stock's 50 day moving average price is $57.78 and its 200 day moving average price is $70.34. The firm has a market capitalization of $7.17 billion, a P/E ratio of 39.60, a price-to-earnings-growth ratio of 1.58 and a beta of 1.19.

Globus Medical announced that its board has authorized a stock repurchase plan on Thursday, May 15th that allows the company to buyback $500.00 million in shares. This buyback authorization allows the medical device company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GMED. Farther Finance Advisors LLC raised its holdings in Globus Medical by 145.5% in the first quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company's stock valued at $30,000 after acquiring an additional 240 shares in the last quarter. Larson Financial Group LLC raised its holdings in Globus Medical by 1,007.7% in the first quarter. Larson Financial Group LLC now owns 432 shares of the medical device company's stock valued at $32,000 after acquiring an additional 393 shares in the last quarter. Parallel Advisors LLC raised its holdings in Globus Medical by 62.1% in the first quarter. Parallel Advisors LLC now owns 504 shares of the medical device company's stock valued at $37,000 after acquiring an additional 193 shares in the last quarter. Versant Capital Management Inc raised its holdings in Globus Medical by 932.1% in the first quarter. Versant Capital Management Inc now owns 547 shares of the medical device company's stock valued at $40,000 after acquiring an additional 494 shares in the last quarter. Finally, Whittier Trust Co. raised its holdings in Globus Medical by 46.5% in the first quarter. Whittier Trust Co. now owns 580 shares of the medical device company's stock valued at $42,000 after acquiring an additional 184 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.